News Release

Journal Article Cites HemoVoid™ in Proteomic Study of JAK mutation and cardiovascular risk

MONMOUTH JUNCTION, NJ, May 24, 2022 -- Biotech Support Group reports on a research article describing the simplicity and efficiency of their hemoglobin depletion technology for enriching red cell proteins, in order to assess the proteomic differences associated with a JAK mutation relative to normal controls.

The citation is:

Liu, Wenli, et al. "Erythroid lineage Jak2 V617F expression promotes atherosclerosis through erythrophagocytosis and macrophage ferroptosis." The Journal of Clinical Investigation (2022).

The JAK2V617F (Jak2VF) mutation increases cardiovascular risk in myeloproliferative disorders and in clonal hematopoiesis. To investigate whether selective erythroid Jak2VF expression promotes atherosclerosis, the investigators developed hyperlipidemic Erythropoietin Receptor Cre mice that express Jak2VF in the erythroid lineage (VFEpoR mice). To explore underlying defects promoting oxidative changes in Jak2VF Red Blood Cells (RBC), unbiased proteomics profiling was conducted. The article states “…haemoglobin removal and on-bead digestion, …was based on the protocol in HemoVoid kit. … Samples were first digested with LysC in HVWB (from kit) with protease: protein ratio 1:100 overnight at 37 °C and then with trypsin in HVWB (from kit) with protease: protein ratio 1:30.” The proteomic data showed a prominent increase in EIF2AK1 (also known as heme-regulated inhibitor, HRI) and EIF2A (Left), consistent with increased oxidative stress. Also, there were decreased levels of three key enzymes in glutathione metabolism in VFEpoR RBC. The authors conclude that Erythroid lineage Jak2VF expression leads to qualitative and quantitative defects in RBCs that exacerbate atherosclerosis.

“I am pleased to see that our methods for Hemoglobin removal using our product HemoVoid™, red cell proteome enrichment, and on-bead digestion were all used in this study. Through the use of two different digestion enzymes, LysC and Trypsin, adapted to our Bead-assisted Sample Prep (BASP™) protocol, several proteins were identified by LC-MS that were differentially expressed. This article illustrates how our products can streamline the workflow for red cell proteomics analyzed by LC-MS, in order to discover potential new biomarkers and a better understanding of JAK mutations in disease.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information on HemoVoid™ LC-MS On-Bead For RBC Proteomics, visit:

https://www.biotechsupportgroup.com/HemoVoid-LC-MS-On-Bead-For-RBC-Proteomics-p/hvb.htm

For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com